Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

UK: A recent consensus statement from leading UK medical organizations—including the Association of Anaesthetists, the ...

Feb. 12, 2024 – People with type 2 diabetes taking GLP-1 medicines may experience potentially blinding eye conditions as soon as the day after starting the drugs, and eye doctors are now asking ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...

UK: A recent consensus statement from leading UK medical organizations-including the Association of Anaesthetists,the ...

Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

"We are pleased to announce last patient/last visit in our Phase 2 obesity study and look forward ... loss beyond those achieved with GLP-1 and GIP drugs," continued Dr. Spana.